Does the media refer more to REGN or ROIV?

In the previous week, Regeneron Pharmaceuticals had 45 more articles in the media than Roivant Sciences. MarketBeat recorded 66 mentions for Regeneron Pharmaceuticals and 21 mentions for Roivant Sciences. Regeneron Pharmaceuticals' average media sentiment score of 1.13 beat Roivant Sciences' score of 0.74 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 46 Very Positive mention(s) 2 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ROIV or ARGX?

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 3,035.32 -$299.77M -$0.53 N/A argenex $5.23B 12.25 $1.29B $26.04 39.29

Is ROIV or ARGX more profitable?

argenex has a net margin of 32.19% compared to Roivant Sciences' net margin of -3,534.96%. argenex's return on equity of 43.59% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,534.96% -22.94% -21.53% argenex 32.19% 43.59% 36.66%

Does the media refer more to ROIV or ARGX?

In the previous week, Roivant Sciences had 2 more articles in the media than argenex. MarketBeat recorded 21 mentions for Roivant Sciences and 19 mentions for argenex. Roivant Sciences' average media sentiment score of 0.74 beat argenex's score of 0.40 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MRNA or ROIV more profitable?

Moderna has a net margin of -141.43% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Roivant Sciences -3,534.96% -22.94% -21.53%

Does the media prefer MRNA or ROIV?

In the previous week, Moderna had 59 more articles in the media than Roivant Sciences. MarketBeat recorded 80 mentions for Moderna and 21 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.74 beat Moderna's score of 0.41 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 35 Very Positive mention(s) 16 Positive mention(s) 7 Neutral mention(s) 10 Negative mention(s) 10 Very Negative mention(s) Neutral Roivant Sciences 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ROIV or NTRA?

Natera has higher revenue and earnings than Roivant Sciences. Natera is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 3,035.32 -$299.77M -$0.53 N/A Natera $2.31B 20.39 -$208.16M -$1.36 N/A

Is ROIV or NTRA more profitable?

Natera has a net margin of -7.11% compared to Roivant Sciences' net margin of -3,534.96%. Natera's return on equity of -11.38% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,534.96% -22.94% -21.53% Natera -7.11% -11.38% -7.87%

Does the media refer more to ROIV or NTRA?

In the previous week, Natera had 23 more articles in the media than Roivant Sciences. MarketBeat recorded 44 mentions for Natera and 21 mentions for Roivant Sciences. Natera's average media sentiment score of 1.21 beat Roivant Sciences' score of 0.74 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 32 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media refer more to RVMD or ROIV?

In the previous week, Revolution Medicines had 51 more articles in the media than Roivant Sciences. MarketBeat recorded 72 mentions for Revolution Medicines and 21 mentions for Roivant Sciences. Revolution Medicines' average media sentiment score of 0.86 beat Roivant Sciences' score of 0.74 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 36 Very Positive mention(s) 9 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 4 Very Negative mention(s) Positive Roivant Sciences 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Roivant Sciences (ROIV) Competitors

$34.71 -2.87 (-7.64%)

As of 08/28/2026 04:00 PM Eastern

Compare

ROIV vs. REGN, ARGX, MRNA, NTRA, and RVMD

Should you buy Roivant Sciences stock or one of its competitors? Roivant Sciences's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), Natera (NTRA), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Roivant Sciences compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Roivant Sciences' net margin of -3,534.96%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Regeneron Pharmaceuticals has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.70	$4.50B	$40.46	19.63
Roivant Sciences	$8.26M	3,035.32	-$299.77M	-$0.53	N/A

In the previous week, Regeneron Pharmaceuticals had 45 more articles in the media than Roivant Sciences. MarketBeat recorded 66 mentions for Regeneron Pharmaceuticals and 21 mentions for Roivant Sciences. Regeneron Pharmaceuticals' average media sentiment score of 1.13 beat Roivant Sciences' score of 0.74 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	46 Very Positive mention(s)	2 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals presently has a consensus price target of $800.36, suggesting a potential upside of 0.78%. Roivant Sciences has a consensus price target of $35.14, suggesting a potential upside of 1.23%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.60
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Regeneron Pharmaceuticals beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to argenex?

Roivant Sciences (NASDAQ:ROIV) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,035.32	-$299.77M	-$0.53	N/A
argenex	$5.23B	12.25	$1.29B	$26.04	39.29

In the previous week, Roivant Sciences had 2 more articles in the media than argenex. MarketBeat recorded 21 mentions for Roivant Sciences and 19 mentions for argenex. Roivant Sciences' average media sentiment score of 0.74 beat argenex's score of 0.40 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, argenex has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

argenex has a net margin of 32.19% compared to Roivant Sciences' net margin of -3,534.96%. argenex's return on equity of 43.59% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
argenex	32.19%	43.59%	36.66%

Roivant Sciences currently has a consensus target price of $35.14, suggesting a potential upside of 1.23%. argenex has a consensus target price of $1,157.50, suggesting a potential upside of 13.12%. Given argenex's stronger consensus rating and higher probable upside, analysts clearly believe argenex is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

argenex beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Moderna?

Moderna (NASDAQ:MRNA) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

In the previous week, Moderna had 59 more articles in the media than Roivant Sciences. MarketBeat recorded 80 mentions for Moderna and 21 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.74 beat Moderna's score of 0.41 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	35 Very Positive mention(s)	16 Positive mention(s)	7 Neutral mention(s)	10 Negative mention(s)	10 Very Negative mention(s)	Neutral
Roivant Sciences	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Moderna presently has a consensus price target of $80.53, suggesting a potential downside of 41.64%. Roivant Sciences has a consensus price target of $35.14, suggesting a potential upside of 1.23%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	3 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.17
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Moderna has a net margin of -141.43% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Roivant Sciences has lower revenue, but higher earnings than Moderna. Roivant Sciences is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	28.34	-$2.82B	-$7.99	N/A
Roivant Sciences	$8.26M	3,035.32	-$299.77M	-$0.53	N/A

Summary

Roivant Sciences beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Natera?

Roivant Sciences (NASDAQ:ROIV) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Roivant Sciences currently has a consensus price target of $35.14, suggesting a potential upside of 1.23%. Natera has a consensus price target of $319.38, suggesting a potential downside of 2.11%. Given Roivant Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Roivant Sciences is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

Natera has a net margin of -7.11% compared to Roivant Sciences' net margin of -3,534.96%. Natera's return on equity of -11.38% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Natera	-7.11%	-11.38%	-7.87%

Natera has higher revenue and earnings than Roivant Sciences. Natera is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,035.32	-$299.77M	-$0.53	N/A
Natera	$2.31B	20.39	-$208.16M	-$1.36	N/A

Roivant Sciences has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Natera has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market.

In the previous week, Natera had 23 more articles in the media than Roivant Sciences. MarketBeat recorded 44 mentions for Natera and 21 mentions for Roivant Sciences. Natera's average media sentiment score of 1.21 beat Roivant Sciences' score of 0.74 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	32 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 5.1% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Natera beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Revolution Medicines presently has a consensus target price of $198.89, suggesting a potential downside of 4.32%. Roivant Sciences has a consensus target price of $35.14, suggesting a potential upside of 1.23%. Given Roivant Sciences' higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Revolution Medicines has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Revolution Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Roivant Sciences has lower revenue, but higher earnings than Revolution Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,847.75	-$1.13B	-$8.82	N/A
Roivant Sciences	$8.26M	3,035.32	-$299.77M	-$0.53	N/A

In the previous week, Revolution Medicines had 51 more articles in the media than Roivant Sciences. MarketBeat recorded 72 mentions for Revolution Medicines and 21 mentions for Roivant Sciences. Revolution Medicines' average media sentiment score of 0.86 beat Roivant Sciences' score of 0.74 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	36 Very Positive mention(s)	9 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	4 Very Negative mention(s)	Positive
Roivant Sciences	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

Get Roivant Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ROIV vs. The Competition

Export

Metric	Roivant Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.07B	$3.94B	$7.21B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-65.49	11.62	273.16	25.45
Price / Sales	3,035.32	1,315.05	614.81	86.98
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	5.10	16.53	12.98	6.14
Net Income	-$299.77M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-4.38%	-0.31%	0.13%	-0.80%
1 Month Performance	0.55%	9.80%	7.08%	4.13%
1 Year Performance	190.95%	55.66%	24.67%	15.17%

Roivant Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ROIV Roivant Sciences	2.0218 of 5 stars	$34.71 -7.6%	$35.14 +1.2%	+190.9%	$25.07B	$8.26M	N/A	860	Trending News Analyst Forecast
REGN Regeneron Pharmaceuticals	4.3138 of 5 stars	$828.50 -0.7%	$801.70 -3.2%	+36.8%	$85.87B	$15.53B	20.48	15,410	Trending News
ARGX argenex	4.31 of 5 stars	$1,011.11 -2.8%	$1,118.28 +10.6%	+43.7%	$65.05B	$4.25B	38.83	1,863	Analyst Upgrade
MRNA Moderna	1.4863 of 5 stars	$138.89 -4.3%	$74.31 -46.5%	+472.8%	$57.94B	$1.94B	N/A	4,700	Trending News Analyst Upgrade Gap Down
NTRA Natera	2.4928 of 5 stars	$327.72 -1.3%	$319.38 -2.5%	+93.9%	$47.86B	$2.71B	N/A	6,140	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ROIV) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Roivant Sciences (ROIV) Competitors

ROIV vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does Roivant Sciences compare to Regeneron Pharmaceuticals?

Summary

How does Roivant Sciences compare to argenex?

Summary

How does Roivant Sciences compare to Moderna?

Summary

How does Roivant Sciences compare to Natera?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Roivant Sciences (ROIV) Competitors

ROIV vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does Roivant Sciences compare to Regeneron Pharmaceuticals?

Is REGN or ROIV more profitable?

Which has more volatility and risk, REGN or ROIV?

Do institutionals and insiders hold more shares of REGN or ROIV?

Which has better valuation & earnings, REGN or ROIV?

Does the media refer more to REGN or ROIV?

Do analysts prefer REGN or ROIV?

Summary

How does Roivant Sciences compare to argenex?

Do institutionals & insiders have more ownership in ROIV or ARGX?

Which has better earnings & valuation, ROIV or ARGX?

Does the media refer more to ROIV or ARGX?

Which has more risk and volatility, ROIV or ARGX?

Is ROIV or ARGX more profitable?

Do analysts rate ROIV or ARGX?

Summary

How does Roivant Sciences compare to Moderna?

Does the media prefer MRNA or ROIV?

Which has more volatility & risk, MRNA or ROIV?

Do insiders & institutionals hold more shares of MRNA or ROIV?

Do analysts prefer MRNA or ROIV?

Is MRNA or ROIV more profitable?

Which has preferable valuation and earnings, MRNA or ROIV?

Summary

How does Roivant Sciences compare to Natera?

Do analysts prefer ROIV or NTRA?

Is ROIV or NTRA more profitable?

Which has preferable valuation & earnings, ROIV or NTRA?

Which has more risk & volatility, ROIV or NTRA?

Does the media refer more to ROIV or NTRA?

Do insiders & institutionals have more ownership in ROIV or NTRA?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Do analysts prefer RVMD or ROIV?

Which has more risk and volatility, RVMD or ROIV?

Do institutionals and insiders have more ownership in RVMD or ROIV?

Is RVMD or ROIV more profitable?

Which has stronger earnings and valuation, RVMD or ROIV?

Does the media refer more to RVMD or ROIV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools